Berkshire Hathaway, renowned for its investment prowess under Warren Buffett and Greg Abel, recently divested its holdings in UnitedHealth Group, a move that, in retrospect, appears to have been ill-timed. Despite the conglomerate's sale at a price lower than its acquisition cost, UnitedHealth's stock has experienced a substantial resurgence. This rebound is largely attributed to an unexpected boost in Medicare Advantage funding and a general improvement in the health insurance sector's financial health. The current market dynamics raise a pertinent question for investors: does UnitedHealth Group, now trading above $400, present a compelling buying opportunity?
Berkshire Hathaway's foray into UnitedHealth Group saw them acquiring shares in the second quarter of 2025, when the stock averaged around $380, and exiting in the first quarter of the current year at a price below $300. This divestment occurred just before the stock surged to $420, fueled by positive developments in the health insurance landscape. The timing of Berkshire's decision underscores the inherent volatility and unpredictability of the market, even for seasoned investors like Buffett and Abel.
A significant factor in UnitedHealth's recent stock decline in 2025 was a sharp increase in medical costs, which adversely impacted its medical care ratio. This crucial metric, representing the proportion of insurance premiums spent on claims, rose from 85.5% in 2024 to 88.9% in 2025. Consequently, UnitedHealth's operating earnings witnessed a considerable drop from $32 billion to $19 billion, reflecting the challenges faced by the company during that period.
However, UnitedHealth has since demonstrated a proactive approach to stabilizing its financial performance. By implementing strategic price adjustments and withdrawing from less profitable segments, the company has begun to mend its medical care ratio. Projections for 2026 indicate a recovery, with the ratio expected to settle around 88%, potentially outperforming this target. This focus on cost optimization and efficient pricing strategies is pivotal for restoring UnitedHealth Group's profitability and, by extension, its stock value.
The persistent inflation in healthcare costs within the United States presents a dual-edged sword for insurers. While it necessitates vigilant cost management, it also serves as a long-term catalyst for revenue growth. The healthcare sector's expansion, driven by an aging demographic and heightened emphasis on health outcomes, has led to a remarkable 150% increase in UnitedHealth Group's revenue over the past decade. This trend suggests a continued trajectory of growth, providing a steady stream of premium revenue for the company.
Considering its recent rebound and robust growth potential, UnitedHealth Group's stock currently trades at a market capitalization of approximately $380 billion. While its trailing price-to-earnings (P/E) ratio of 25.5 might appear steep against its current net income of $14.9 billion, this figure does not fully capture the company's anticipated future earnings. Management's guidance, coupled with share repurchases of at least $5 billion this fiscal year, suggests a more favorable outlook. With projected net income ranging from $25 billion to $30 billion in the coming years, the forward P/E ratio could drop to an attractive 15, making UnitedHealth Group an appealing prospect for investors seeking value in the insurance sector.
The recent surge in UnitedHealth Group's stock, following its brief downturn and Berkshire Hathaway's exit, highlights the company's resilience and strategic adjustments in a dynamic healthcare market. The improved medical care ratio, coupled with the enduring tailwind of healthcare inflation and proactive share repurchases, positions UnitedHealth as a potentially strong investment. These factors, alongside its long-term earnings growth potential, indicate that the stock's current valuation might still offer significant upside for discerning investors.